echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Optimising treatment options for cancer patients NTRK gene fusion detection obtains breakthrough medical device identification

    Optimising treatment options for cancer patients NTRK gene fusion detection obtains breakthrough medical device identification

    • Last Update: 2020-06-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    ArcherDX focuses on tackling bottlenecks in the second-generation sequencing of tumor mutation genesIts proprietary and powerful target gene sequencing platform uses proprietary chemical reagents to generate a highly enriched sequencing library to accurately detect gene fusion, point mutations, copy number variation (CNV) and RNA abundance from solid tumors, blood cancers, sarcoma and liquid biopsy samplesin addition, the company's partnership with Bayer is primarily aimed at expanding the accessibility of integrated testing for NTRK1, NTRK2, and NTRK3 gene fusion in patients to help improve treatment options for NTRK fusion cancer patients"cancers that carry the fusion of ntRK genes have long been difficult to detect." Our next-generation sequencing technology uses RNA to provide highly sensitive NTRK fusion detection without having to know any solid tumor fusion information in advance," said DrJason Myers, CEO and co-founder of ArcherDX"
    " to help more patients benefit from Vitrakvi therapy, it is critical to develop next-generation sequencing kits," said Robert LaCaze, Head of Strategy, Oncology, Bayer OncologyReferences:ArcherDX Receives The SMetS Device Device To Detect NTRK Gene FusionsRetrieved 2020-05-19, from
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.